Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 2 of 4: Calculated dose-response metrics. - Dataset (ID:20269)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Biological Replicate ID | Conc Unit | GR50 | GEC50 | GRmax | GRinf | GR Hill Coefficient | GR_AOC | GR r2 | Nominal Division Rate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BT-20 | TNBC | Basal A | TCS PIM-1 1 | Pim kinase | PIM | 11854.135 | uM | inf | inf | 0.8384 | 0.8384 | 0.0000 | 0.0710 | 0.5319 | 1.3170 | |
BT-483 | HR+ | Luminal | Pevonedistat | NAE1 | NAE1 | 11855.135 | uM | inf | inf | 0.7998 | 0.7998 | 0.0000 | 0.2110 | 0.0000 | 0.6394 | |
21MT-1 | HER2amp | - | MG-132 | Proteasome | Proteasome | 14191.189 | uM | inf | inf | -0.1161 | -0.1161 | 0.0000 | 0.5482 | 0.5418 | 2.9704 | |
21MT-1 | HER2amp | - | MG-132 | Proteasome | Proteasome | 14191.189 | uM | inf | inf | -0.1161 | -0.1161 | 0.0000 | 0.5482 | 0.5418 | 2.9704 | |
184A1 | NM | Basal | (Z)-4-Hydroxytamoxifen | ESR1 | 9047.132 | uM | inf | inf | 0.4055 | 0.4055 | 0.0000 | 0.2074 | 0.3073 | 0.6985 | ||
AU565 | HER2amp | Luminal | Cisplatin | DNA cross-linker | DNA cross-linker | 9146.049 | uM | inf | inf | 0.5485 | 0.5485 | 0.0000 | 0.3293 | 0.0796 | 1.1054 | |
BT-474 | HER2amp | Luminal | Epirubicin | TOP2 | TOP | 7798.017 | uM | inf | inf | 0.5325 | 0.5325 | 0.0000 | 0.2112 | 0.5662 | 1.4161 | |
21MT-1 | HER2amp | - | Ribavirin | 15382.211 | uM | inf | inf | 0.9683 | 0.9683 | 0.0000 | 0.0416 | 0.0000 | 1.1714 | |||
AU565 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 9146.122 | uM | inf | inf | 0.9694 | 0.9694 | 0.0000 | -0.0404 | -1.9847 | 1.3408 | |
600MPE | HR+ | Luminal | Ixabepilone | TUBB | TUBB | 5899.094 | uM | inf | inf | -0.9801 | -0.9801 | 0.0000 | 0.9711 | 0.3677 | 1.0334 | |
BT-20 | TNBC | Basal A | Ro 32-0432 | PKC | PKC | 10581.142 | uM | inf | inf | 1.0451 | 1.0451 | 0.0000 | 0.0021 | -0.0023 | 0.7885 | |
600MPE | HR+ | Luminal | Pemetrexed | TYMS/DHFR/GARFT | TYMS | 5898.095 | uM | inf | inf | 0.3076 | 0.3076 | 0.0000 | 0.6877 | 0.0000 | 0.6975 | |
BT-20 | TNBC | Basal A | Methotrexate | DHFR | Metabolism | 5904.085 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0334 | -1.4110 | 1.2247 | |
AU565 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 10880.145 | uM | inf | inf | 0.9804 | 0.9804 | 0.0000 | 0.0621 | 0.0247 | 1.4751 | |
BT-20 | TNBC | Basal A | AG1024 | IGF1R | RTK | 5902.066 | uM | inf | inf | 0.9990 | 0.9990 | 0.0000 | -0.0235 | -0.9254 | 1.1775 | |
600MPE | HR+ | Luminal | Pemetrexed | TYMS/DHFR/GARFT | TYMS | 5899.094 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0167 | -0.1754 | 1.0334 | |
CAMA-1 | HR+ | Luminal | AS-252424 | PI3K | PI3K | 12070.158 | uM | inf | inf | 0.8032 | 0.8032 | 0.0000 | 0.0455 | 0.3230 | 1.1252 | |
AU565 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 7794.018 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0500 | -inf | 1.6812 | |
BT-474 | HER2amp | Luminal | Glycyl-H-1152 | ROCK2 | 12178.16 | uM | inf | inf | 0.7508 | 0.7508 | 0.0000 | 0.1609 | 0.0357 | 0.7392 | ||
BT-474 | HER2amp | Luminal | Pemetrexed | TYMS/DHFR/GARFT | TYMS | 5905.095 | uM | inf | inf | 0.9541 | 0.9541 | 0.0000 | 0.0237 | 0.0563 | 0.9590 | |
184A1 | NM | Basal | Cetuximab | EGFR | ErbB | 7787.018 | uM | inf | inf | 0.4652 | 0.4652 | 0.0000 | 0.3838 | -0.0013 | 0.3791 | |
600MPE | HR+ | Luminal | GSK923295 | CENPE | Kinesin | 9118.001 | uM | inf | inf | 0.5960 | 0.5960 | 0.0000 | 0.1146 | 0.4985 | 1.0946 | |
21NT | HER2amp | - | Ribavirin | 15383.211 | uM | inf | inf | 1.0074 | 1.0074 | 0.0000 | 0.0469 | 0.0000 | 1.0341 | |||
HBL-100 | Unknown | Unknown | Cetuximab | EGFR | ErbB | 7807.042 | uM | inf | inf | 1.0098 | 1.0098 | 0.0000 | -0.0392 | -7.7987 | 2.0250 | |
HBL-100 | Unknown | Unknown | AG1478 | EGFR | ErbB | 7807.016 | uM | inf | inf | 0.9359 | 0.9359 | 0.0000 | 0.0541 | 0.4439 | 2.1516 |